GSK vs JANX · P/E 13, $103.31B cap vs rev $10.3M
GlaxoSmithKline PLC ADR (GSK) versus Janux Therapeutics Inc (JANX) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. JANX currently screens at market cap $1.49B.
Not investment advice. Open the GSK and JANX stock pages for the full models.
Not investment advice.